This work put forward LSNP regulated gene expression based breast and ovarian cancer risk prediction model LsGCRPred (LSNP-Gene Interaction Based Cancer Risk Prediction Model), which accounts for the tissue-specificity of lncRNAs as well the benefit for individuals with predisposing conditions.
Abstract
Long non-coding RNAs (lncRNAs) and single nucleotide polymorphisms (SNPs) within them play crucial role in cancer susceptibility and disease outcomes. Breast and ovarian cancers, characterized by genetic heterogeneity, present significant challenges for precise diagnosis and treatment. Despite recent advancements in personalized medicine, inclusion of lncRNA-SNP (LSNP) markers into cancer risk detection panels remains limited. In this work, we put forward LSNP regulated gene expression based breast and ovarian cancer risk prediction model LsGCRPred (LSNP-Gene Interaction Based Cancer Risk Prediction Model). Notably, our approach accounts for the tissue-specificity of lncRNAs as well the benefit for individuals with predisposing conditions. Additionally, pathway analysis revealed the involvement of the LSNP interacting genes in key cancer regulating pathways. TaqMan genotyping and qPCR were performed to confirm the presence of selected LSNPs in ovarian and breast cancer cell lines along with the significant expression of the lncRNA and associated gene transcripts. These findings highlight previously overlooked genetic variants within lncRNA loci and their regulatory impact on disease outcomes, providing insights into personalized cancer diagnosis and treatment strategies. The tool LsGCRPred can be accessed as a standalone version on GitHub. Github Link: https://github.com/zglabDIB/LsGCRPred
This computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer, which should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.
M. Acencio, Xin-Hui Wang, Flavia R. Rotea Mangone et al.· International Journal of Mol...· 0 citations
The findings suggest that HTR2A variants and miRNA profiles may serve as potential biomarkers for risk stratification and targeted therapeutic approaches in TNBC, and help scientists find better ways to detect and treat breast cancer in AA women.
Nicole Retland, Karl M. Thompson, Joseph I. Aubee et al.· Journal of breast cancer res...· 0 citations
This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.
Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al.· Current Genetic Medicine Rep...· 0 citations
It is suggested that miRNA out-seed variants predicted to regulate WNT/NOTCH pathway nodes may contribute to breast cancer susceptibility in a subtype-dependent manner, and replication in a larger population and functional validation of allele-specific miRNA–target interactions are warranted.
Thanh Thi Ngoc Nguyen, T. T. Duong, N. Nguyen et al.· Egyptian Journal of Medical...· 0 citations
Findings support hsa-miR-200a as a potential breast cancer-associated miRNA biomarker candidate and highlight the utility of integrative transcriptomic and exploratory clinical serum approaches for future precision diagnostics.
Kwangmin Park, Eun You Kim, Eun Ju Lee et al.· Genes & Genomics· 0 citations
This study integrates multi-omics datasets to identify candidate biomarkers that may influence TNBC progression and modulate therapeutic response and nominate CCND2 and KIF1A as candidate biomarkers and potential therapeutic targets in TNBC.
Roberto Aguilar, Victor Wang, Shane Deng· Journal of Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.